霍乱结合疫苗的可规模化生产与免疫原性
为开发可保护5岁以下幼儿、诱导长期免疫并可纳入EPI的霍乱疫苗,本研究通过可规模化工艺生产了含O1 Inaba OSP的霍乱结合疫苗(CCV),并进行了临床前免疫原性评估。在临床前测试中,疫苗诱导了OSP和LPS特异性IgG/IgM应答、杀弧菌应答、记忆B细胞应答及攻毒模型保护,铝佐剂增加了OSP特异性免疫应答。
要点
- CCV通过可规模化工艺生产,含O1 Inaba OSP偶联rTTHc。
- 临床前测试中CCV诱导抗体、杀弧菌、记忆B细胞及保护应答。
- 铝磷酸盐佐剂可增强OSP特异性免疫应答。
核心结论
- CCV可规模化生产,临床前显示免疫原性和保护性,支持人体评价。
研究设计与样本
- 临床前研究:生产两批非GMP CCV并表征理化性质和免疫原性,在有无铝磷酸盐佐剂下评估。
主要发现
- CCV诱导OSP和LPS特异性IgG和IgM应答、杀弧菌应答、记忆B细胞应答及V. cholerae O1攻毒模型保护。
- 添加铝磷酸盐佐剂增加了OSP特异性免疫应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a need to develop cholera vaccines that are protective in young children under 5 years of age, which induce long-term immunity, and which can be incorporated into the Expanded Programme of Immunization (EPI) in cholera-endemic countries. The degree of protection afforded by currently available oral cholera vaccines (OCV) to young children is significantly lower than that induced by vaccination of older vaccine recipients. Immune responses that protect against cholera target the O-specific polysaccharide (OSP) of Vibrio cholerae, and young children have poor immunological responses to bacterial polysaccharides, which are T cell independent antigens. To overcome this, we have developed a cholera conjugate vaccine (CCV) containing the OSP of V. cholerae O1, the main cause of endemic and epidemic cholera. Here, we describe production of CCV through a scalable manufacturing process and preclinical evaluation of immunogenicity in the presence and absence of aluminum phosphate (alum) as an adjuvant. The vaccine displays V. cholerae O1 Inaba OSP in sun-burst display via single point attachment of core oligosaccharide to a recombinant tetanus toxoid heavy chain fragment (rTTHc). Two different pilot-scale production batches of non-GMP CCV were manufactured and characterized in terms of physico-chemical properties and immunogenicity. In preclinical testing, the vaccine induced OSP- and lipopolysaccharide (LPS)-specific IgG and IgM responses, vibriocidal responses, memory B cell responses, and protection in a V. cholerae O1 challenge model. The addition of alum to the administered vaccine increased OSP-specific immune responses. These results support evaluation of CCV in humans.
引用
- Jeon S, Kelly M, Yun J, et al. Scalable production and immunogenicity of a cholera conjugate vaccine. Vaccine. 2021. PMID: 34716040. doi:10.1016/j.vaccine.2021.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。